Saúdská Arábie - angličtina - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

sudair pharma company, saudi arabia - fosaprepitant dimeglumine - powder for solution for injection - 150 mg

Japonsko - angličtina - すりの適正使用協議会 RAD-AR Council, Japan

nippon kayaku - fosaprepitant meglumine - injection

Evropská unie - angličtina - EMA (European Medicines Agency)

merck sharp & dohme b.v. - fosaprepitant - vomiting; cancer - antiemetics and antinauseants, - prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults and paediatric patients aged 6 months and older.ivemend 150 mg is given as part of a combination therapy.

Spojené státy - angličtina - NLM (National Library of Medicine)

athenex pharmaceutical division, llc. - fosaprepitant dimeglumine (unii: d35fm8t64x) (aprepitant - unii:1nf15yr6uy) - fosaprepitant for injection, in combination with other antiemetic agents, is indicated in adults for the prevention of: - acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (hec) including high-dose cisplatin. - delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (mec). limitations of use - fosaprepitant for injection has not been studied for the treatment of established nausea and vomiting. pediatric use information is approved for merck sharp & dohme corp., a subsidiary of merck & co., inc.'s emend (fosaprepitant) for injection. however, due to merck sharp & dohme corp., a subsidiary of merck & co., inc.'s marketing exclusivity rights, this drug product is not labeled with that pediatric information. fosaprepitant for injection is contraindicated in patients: - who are hypersensitive to any component of the product. hypersensitivity reactions including anaphylactic reactions

Malajsie - angličtina - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

mega lifesciences sdn. bhd. - fosaprepitant dimeglumine -

Spojené státy - angličtina - NLM (National Library of Medicine)

merck sharp & dohme corp. - fosaprepitant dimeglumine (unii: d35fm8t64x) (aprepitant - unii:1nf15yr6uy) - emend® for injection, in combination with other antiemetic agents, is indicated in adults for the prevention of: - acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (hec) including high-dose cisplatin. - delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (mec). limitations of use - emend has not been studied for the treatment of established nausea and vomiting. emend is contraindicated in patients: - who are hypersensitive to any component of the product. hypersensitivity reactions including anaphylactic reactions, flushing, erythema, and dyspnea have been reported [see warnings and precautions (5.2), adverse reactions (6.2)] . - taking pimozide. inhibition of cyp3a4 by aprepitant, the active moiety, could result in elevated plasma concentrations of this drug, which is a cyp3a4 substrate, potentially causing serious or life-threatening reactions, such as qt prolongation, a

Spojené státy - angličtina - NLM (National Library of Medicine)

merck sharp & dohme corp. - fosaprepitant dimeglumine (unii: d35fm8t64x) (aprepitant - unii:1nf15yr6uy) - emend® for injection, in combination with other antiemetic agents, is indicated in adults and pediatric patients 6 months of age and older for the prevention of: - acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (hec) including high-dose cisplatin. - delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (mec). limitations of use - emend has not been studied for the treatment of established nausea and vomiting. emend is contraindicated in patients: - who are hypersensitive to any component of the product. hypersensitivity reactions including anaphylactic reactions, flushing, erythema, and dyspnea have been reported [see warnings and precautions (5.2), adverse reactions (6.2)] . - taking pimozide. inhibition of cyp3a4 by aprepitant, the active moiety, could result in elevated plasma concentrations of this drug, which is a cyp3a4 substrate, potentially causing serious or life-t

Spojené státy - angličtina - NLM (National Library of Medicine)

merck sharp & dohme corp. - fosaprepitant dimeglumine (unii: d35fm8t64x) (aprepitant - unii:1nf15yr6uy) - emend® for injection, in combination with other antiemetic agents, is indicated in adults and pediatric patients 6 months of age and older for the prevention of: - acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (hec) including high-dose cisplatin. - delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (mec). limitations of use - emend has not been studied for the treatment of established nausea and vomiting. emend is contraindicated in patients: - who are hypersensitive to any component of the product. hypersensitivity reactions including anaphylactic reactions, flushing, erythema, and dyspnea have been reported [see warnings and precautions (5.2), adverse reactions (6.2)] . - taking pimozide. inhibition of cyp3a4 by aprepitant, the active moiety, could result in elevated plasma concentrations of this drug, which is a cyp3a4 substrate, potentially causing serious or life-t

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

herbal world pty ltd - turnera diffusa, quantity: 37.5 microgram/ml (equivalent: turnera diffusa, qty 150 microgram/ml; equivalent: beta-arbutin, qty 1.05 microgram/ml); oenothera biennis, quantity: 25 microgram/ml (equivalent: oenothera biennis, qty 100 microgram/ml); dioscorea villosa, quantity: 625 microgram/ml (equivalent: dioscorea villosa, qty 2.5 mg/ml); malpighia glabra, quantity: 82.5 microgram/ml (equivalent: malpighia glabra, qty 825 microgram/ml; equivalent: ascorbic acid, qty 10 microgram/ml); matricaria chamomilla, quantity: 125 microgram/ml (equivalent: matricaria chamomilla, qty 500 microgram/ml) - oral liquid - excipient ingredients: potable water; sodium benzoate; carbon dioxide; sucrose; maltodextrin; citric acid; vanillin; linalool; delta-decalactone; neryl acetate; ethyl propionate; ethyl butyrate; citronellal; anethole; methyl benzoate; buchu leaf oil; dimethyl anthranilate; propylene glycol; phenethyl alcohol; mandarin oil; benzyl acetate; ethyl acetate; ethanol; orange oil; phenylacetaldehyde; cis-3-hexen-1-ol; geraniol; trans-2-hexenol; terpinen-4-ol; limonene; citral; maltol; menthone; ethyl caprate; petitgrain oil; isoamyl acetate; davana oil; rose oil; linalyl acetate; geranyl acetate; bergamot oil; benzaldehyde; l-menthyl acetate; orange flower oil; ethyl enantate; benzyl alcohol; alpha-phellandrene; isovaleric acid; geranyl butyrate; lemon oil terpeneless; cinnamon leaf oil; piperonal; gamma-decalactone; jasmine absolute; ginger oil; terpineol; hexyl acetate; acetic acid; 4-(para-hydroxyphenyl)-2-butanone; decanal; alpha-irone; alpha-terpineol; benzyl benzoate; caprylic aldehyde; butylated hydroxytoluene; nerol; sweet orange oil terpenes and terpenoids; geranyl propionate; gamma-heptalactone; linalyl isobutyrate; ethyl salicylate; 2,6-nonadien-1-ol; dwarf pine-needle oil; ambrette seed oil; methyl anthranilate; dimethyl sulfide; lauryl aldehyde; terpinyl acetate - helps reduce/decrease free radical damage to body cells ; maintain/support cardiovascular system health ; decrease/reduce/relieve diarrhoea ; help maintain/support emotional wellbeing ; decrease/reduce/relieve symptoms of common cold ; decrease/reduce/relieve cough ; decrease/reduce/relieve throat irritation